RxDoctor Payments Data

Winona Tse, MD

Neurology · New York, NYNPI 1831160092

Payments from drug & device makers

$769,339in general payments, 2019–2025

Across 641 payments — averaging $1200.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$227K
  • Biogen$174K
  • UCB SA$150K
  • Ipsen Innovation$64K
  • Teva Pharmaceuticals USA, Inc.$60K
  • H. Lundbeck A S$47K
  • plus $47K from 22 others
$5,993in research payments, 2019–2025

Across 5 payments — averaging $1198.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$4K
  • Lundbeck LLC$1K
  • Biogen$1K

What the payments were for

  • Consulting fees$19,16745%
  • Speaking & faculty fees$9202%
  • Travel & lodging$6,08214%
  • Food & beverage$16,37838%
  • Education$3451%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769,339 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$392,740
Medicare patients
610
Services billed
32,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine31$201,750
Tetrabenazine36$85,189
NuplazidPimavanserin Tartrate17$81,481
RytaryCarbidopa/Levodopa18$43,713
Carbidopa-LevodopaCarbidopa/Levodopa871$35,813
Carbidopa45$12,002
Entacapone58$11,987
Carbidopa-Levodopa ErCarbidopa/Levodopa231$8,706
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone17$4,786
Mirtazapine146$3,651
AmantadineAmantadine Hcl55$3,625
Rivastigmine18$2,106
Donepezil Hcl247$2,064
Propranolol Hcl ErPropranolol Hcl28$1,997
Primidone149$1,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$60,423$201,75031 claims
Acadia Pharmaceuticals IncNuplazid$4,470$81,48117 claims
Amneal Pharmaceuticals LLCRytary$1,125$43,71318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →